|
Name |
Bassiatin
|
Molecular Formula | C15H19NO3 | |
IUPAC Name* |
(3S,6R)-3-benzyl-4-methyl-6-propan-2-ylmorpholine-2,5-dione
|
|
SMILES |
CC(C)[C@@H]1C(=O)N([C@H](C(=O)O1)CC2=CC=CC=C2)C
|
|
InChI |
InChI=1S/C15H19NO3/c1-10(2)13-14(17)16(3)12(15(18)19-13)9-11-7-5-4-6-8-11/h4-8,10,12-13H,9H2,1-3H3/t12-,13+/m0/s1
|
|
InChIKey |
YOKBTBNVNCFOBF-QWHCGFSZSA-N
|
|
Synonyms |
Bassiatin; (3S,6R)-3-benzyl-6-isopropyl-4-methyl-2,5-morpholinedione; (3S,6R)-3-benzyl-4-methyl-6-(propan-2-yl)morpholine-2,5-dione; (3S,6R)-4-methyl-6-(1-methylethyl)-3-(phenylmethyl)-2,5-morpholinedione; (3S,6R)-4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione; CHEBI:65465; AT25355; Q27133907; (3S,6R)-3-benzyl-4-methyl-6-propan-2-ylmorpholine-2,5-dione
|
|
CAS | NA | |
PubChem CID | 10038289 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 261.32 | ALogp: | 2.8 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 3 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 46.6 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.784 |
Caco-2 Permeability: | -4.571 | MDCK Permeability: | 0.00006760 |
Pgp-inhibitor: | 0.036 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.005 |
30% Bioavailability (F30%): | 0.009 |
Blood-Brain-Barrier Penetration (BBB): | 0.942 | Plasma Protein Binding (PPB): | 61.52% |
Volume Distribution (VD): | 0.934 | Fu: | 36.04% |
CYP1A2-inhibitor: | 0.083 | CYP1A2-substrate: | 0.133 |
CYP2C19-inhibitor: | 0.261 | CYP2C19-substrate: | 0.902 |
CYP2C9-inhibitor: | 0.117 | CYP2C9-substrate: | 0.433 |
CYP2D6-inhibitor: | 0.012 | CYP2D6-substrate: | 0.356 |
CYP3A4-inhibitor: | 0.108 | CYP3A4-substrate: | 0.642 |
Clearance (CL): | 7.035 | Half-life (T1/2): | 0.475 |
hERG Blockers: | 0.016 | Human Hepatotoxicity (H-HT): | 0.76 |
Drug-inuced Liver Injury (DILI): | 0.951 | AMES Toxicity: | 0.027 |
Rat Oral Acute Toxicity: | 0.098 | Maximum Recommended Daily Dose: | 0.032 |
Skin Sensitization: | 0.082 | Carcinogencity: | 0.054 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.022 |
Respiratory Toxicity: | 0.034 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004822 | 1.000 | D06BYV | 0.379 | ||||
ENC002255 | 0.500 | D05EPM | 0.362 | ||||
ENC001909 | 0.458 | D06IXT | 0.361 | ||||
ENC004861 | 0.438 | D0P6UB | 0.361 | ||||
ENC003593 | 0.429 | D05BMG | 0.356 | ||||
ENC002563 | 0.418 | D0T3LF | 0.356 | ||||
ENC005470 | 0.415 | D07RGW | 0.352 | ||||
ENC003324 | 0.408 | D08EOD | 0.348 | ||||
ENC004609 | 0.407 | D08UMH | 0.329 | ||||
ENC005484 | 0.405 | D0G1OZ | 0.328 |